⚡ FAST WATCH — updated weekly

Not yet peer-reviewed, but worth following:

• July 3: The cancer‑Alzheimer's paradox — epidemiological and mechanistic evidence shows inverse relationship. APOE4, immune signalling, and cystatin‑C/TREM2 pathways implicated. Caveats: Association ≠ causation; cell‑type‑specific effects. Source →
• June 29: R‑loop export drives inflammaging; selinexor (KPT‑330) reverses it in mice — MD Anderson study in Nature Aging. Senescent cells export R‑loops, triggering inflammation. FDA‑approved cancer drug blocked this, reducing inflammation, liver damage, fat gain, muscle loss; extended lifespan in models. Caveats: Mouse study; human trials needed. Source →
• June 29: FGF21 gene therapy improves healthspan in old mice — Universitat Autònoma de Barcelona study. One‑time AAV‑FGF21 increased life expectancy by 20.5%; improved metabolism, liver/kidney/heart function, memory in old mice. Caveats: Mouse study; human trial for MASH is ongoing (different indication). Source →
• June 29: Heliconius butterflies – a new model for healthy aging — study in Nature Communications. Some species live 3x longer than relatives with no age‑related decline. Caveats: Evolutionary model; mechanisms not yet translated. Source →
• June 29: First human trial to rejuvenate exhausted immune cells (SenTcell) — Phase I trial expected 2026. Targets senescent/exhausted T‑cells to restore immune function. Caveats: Phase I; safety only. Source →
• June 29: BioAge NLRP3 inhibitor (BGE‑102) enters Phase 2 trial (QUELL‑CV) — oral anti‑inflammatory for cardiovascular risk. Phase I: hsCRP reductions up to 86%. Caveats: Early phase; cardiovascular outcomes pending. Source →
• June 25: Minicircle klotho gene therapy — unapproved commercial longevity gene therapy available at offshore clinics. Human data unpublished (n=24, no control group). Mouse studies show klotho extends lifespan (~30%) and improves memory, but another study found bleeding and ulcers. Caveats: No regulatory oversight; risk to patients and field legitimacy. Source →
• June 20: Cell‑type‑specific biological age from a blood test — Stanford (Wyss-Coray Lab) study in Nature Medicine. SomaScan proteomics platform estimates biological age for 40+ cell types from a single blood draw (n=60,000+). Extreme astrocyte aging predicted Alzheimer's (HR comparable to APOE4); extreme myocyte aging predicted ALS (12.7x higher risk); extreme aging across 20+ cell types associated with 34% 15‑year survival vs 90% for normal agers. Caveats: Research‑grade platform; cohorts mostly older and Caucasian; association ≠ causation. Source →
• June 18: Blood test detects ALS risk years before symptoms — NfL (neurofilament light chain) biomarker study (Nature Medicine). Elevated NfL associated with 12.7‑fold higher risk of developing ALS, detectable up to 5 years before symptom onset. Caveats: Retrospective study; NfL elevation not specific to ALS; no pre‑symptomatic treatment yet. Source →

📬 Full citations added to monthly archive when peer-reviewed. Subscribe for the monthly digest.

Behind the archive

Dr. Andjelka Stones

Researcher & curator

🤖

MedElle

AI collaborator & research assistant

Global New World is a human‑AI collaboration. Every update is co‑constructed from peer‑reviewed science — no automation, no commercial bias.